18FDG-PET

RADIATION2 trials

Sponsors

Korea University, Jean-Luc Balligand

Conditions

AtherosclerosisHypertrophy, Left Ventricular

Phase 2

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

CompletedNCT02599480

Jean-Luc BalligandHypertrophy, Left Ventricular

Start: 2016-09-12End: 2022-02-16Updated: 2025-02-10

Unknown Phase

Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)

CompletedNCT02394743

Korea UniversityAtherosclerosis

Start: 2011-03-31End: 2016-09-30Updated: 2016-09-08

Related Papers

Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.

2025-03-226 citations

Repurposing the β<sub>3</sub>-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease

JAMA Cardiology2023-09-209 citations